A medical conference in Istanbul is hearing the argument that GLP-1 agonists could do for obesity what tobacco litigation did for smoking — move the moral weight off the individual and onto the industry that engineered the demand. In the popular health press, simultaneously, a different argument is taking shape, this one less editorial than testimonial: patients on these drugs are reporting a flattening of pleasure that extends past food, into s…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.